Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenue
Revenue	$ 170,276	$ 185,308	$ 154,344
Operating expenses
Cost of revenue	75,553	57,909	49,301
Research and development	122,117	141,756	142,343
Sales and marketing	88,579	95,603	95,465
General and administrative	83,934	88,527	74,502
Amortization of intangible assets	1,699	1,699	1,699
Impairment of right-of-use and related long-lived assets	25,429
Total operating expenses	397,311	385,494	363,310
Loss from operations	(227,035)	(200,186)	(208,966)
Interest and other income, net	15,531	4,056	1,668
Interest expense	(13,800)	(4,238)
Net loss	(225,304)	(200,368)	(207,298)
Add: Net loss attributable to noncontrolling interest	54	177	19
Net loss attributable to Adaptive Biotechnologies Corporation	$ (225,250)	$ (200,191)	$ (207,279)
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic	$ (1.56)	$ (1.4)	$ (1.48)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic	144,383,294	142,515,917	140,354,915
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted	$ (1.56)	$ (1.4)	$ (1.48)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted	144,383,294	142,515,917	140,354,915